5-溴-2-吡啶羧酸 | 30766-11-1

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-2-吡啶羧酸
• 中文别名: 5-溴吡啶甲酸；2-羧酸-5-溴吡啶；5-溴-2-吡啶甲酸；2-羧基-5-溴吡啶；5-溴吡啶-2-羧酸；5-溴吡啶羧酸；5-溴-2-羧基吡啶；5-溴吡啶-2-甲酸
• 英文名称: 5-bromoisonicotinic acid
• 英文别名: 5-bromopicolinic acid；5-bromopyridine-2-carboxylic acid；5-bromopyridinecarboxylic acid；5-bromo-2-pyridinecarboxylic acid；5-bromo-pyridin-2-carboxylic acid；(5-bromopyridin-2-yl)carboxylic acid
• CAS: 30766-11-1
• 化学式: C₆H₄BrNO₂
• mdl: MFCD00234149
• 分子量: 202.007
• InChiKey: MNNQIBXLAHVDDL-UHFFFAOYSA-N

物化性质

• 熔点：
  173-175°C
• 沸点：
  319.5±27.0 °C(Predicted)
• 密度：
  1.813±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇。
• 稳定性/保质期：

  如果遵照规格使用和储存，则不会分解，也未有已知危险反应。避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥处。同时，确保工作环境有良好的通风或排气装置。

SDS

5-Bromopicolinic Acid Revision number: 1
SAFETY DATA SHEET

---

Section 1. BASE INFORMATION
Product name: 5-Bromopicolinic Acid

Revision number: 1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the GHS
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Category 2
Skin corrosion/irritation
Serious eye damage/eye irritation Category 2A
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements
Pictograms or hazard symbols
Signal word Warning
Hazard statement Causes skin irritation
Causes serious eye irritation
Precautionary statements
[Prevention] Wash hands thoroughly after handling.
Wear protective gloves/eye protection/face protection.
[Response] IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Component(s): 5-Bromopicolinic Acid
Percent: >97.0%(GC)(T)
CAS Number: 30766-11-1
Synonyms: 5-Bromo-2-pyridinecarboxylic Acid
Chemical Formula: C6H4BrNO2

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
5-Bromopicolinic Acid

---

Section 4. FIRST AID MEASURES
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards: Take care as it may decompose upon combustion or in high temperatures to
generate poisonous fume.
Specific methods: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Storage
Keep container tightly closed. Store in a cool and dark place.
Storage conditions:
Store away from incompatible materials such as oxidizing agents.
Packaging material: Law is followed.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: crystal - powder
Color: White - Slightly pale reddish yellow
Odor: No data available
pH: No data available
5-Bromopicolinic Acid

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Melting point/freezing point:176 °C
Boiling Point/Range: No data available
Flash Point: No data available
Explosive limits
Lower: No data available
No data available
Upper:
Density: No data available
Soluble in : Methanol
Solubility:

---

Section 10. STABILITY AND REACTIVITY
Stability: Stable under proper conditions.
Reactivity: No special reactivity has been reported.
Incompartible materials: oxidizing agents
Hazardous Decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx), Hydrogen bromide
Products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
No data available
NTP =
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobillity in soil
log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not Listed

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26,
2002): Safe use and production, the storage of a dangerous chemical, transport, loading and unloading were
prescribed.
5-Bromopicolinic Acid

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

5-溴-2-吡啶羧酸用作医药化工中间体。

应用

5-溴-2-吡啶羧酸是有机合成中间体和医药中间体，主要用于实验室有机合成过程和化工医药研发过程中。

制备方法

以5-溴-2-甲基吡啶为原料，用水作为溶剂，在80°C的温度下加热。分批加入高锰酸钾，并维持反应温度在85-90°C之间，加热时间为60-100分钟。随后将反应物进行蒸馏、过滤并调节pH值，冷却后结晶得到5-溴-2-吡啶羧酸。

反应信息

• 作为反应物：
  描述：

  5-溴-2-吡啶羧酸 在 硫酸 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 7.0h， 生成 5-氰基-吡啶-2-羧酸甲酯
  参考文献：
  名称：

  [EN] N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A
  [FR] MODULATEURS NÉGATIFS N-ARYLMÉTHYL SULFONAMIDE DE NR2A

  摘要：

  公开号：

  WO2015048503A3
• 作为产物：
  描述：

  6-甲基-3-吡啶羰基叠氮化物 在 氢氧化钾 、 potassium permanganate 、 potassium nitrite 、 硫酸 作用下， 生成 5-溴-2-吡啶羧酸
  参考文献：
  名称：

  Graf, Journal fur praktische Chemie (Leipzig 1954), 1932, vol. <2> 133, p. 36,49

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-溴-2-氰基吡啶 、 sodium hydroxide 、 、 氨 、 溶剂黄146 在 丙酮 、 5-溴-2-吡啶羧酸 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 以to provide 5-bromopyridine-2-carboxylic acid (Compound B) as a solid的产率得到5-溴-2-吡啶羧酸
  参考文献：
  名称：

  Therapeutic agents useful for treating pain

  摘要：

  本发明公开了一个化合物的公式：其中Ar1，Ar2，X，Z1，Z2，R3和m如本文所述或其药学上可接受的盐（“吡啶烯化合物”）;包括有效量的吡啶烯化合物的组合物;以及治疗或预防动物疼痛或其他病症的方法，包括向需要的动物投与有效量的吡啶烯化合物。

  公开号：

  US20060241117A1

文献信息

• ANDROGEN RECEPTOR MODULATING CARBOXAMIDES
  申请人：Törmakängas Olli

  公开号：US20140094474A1

  公开（公告）日：2014-04-03

  Compounds of formula (I) or (II) wherein R x , R z , R 9 , R 10 , R 14 , R 14 ′, R 15 , R 15 ′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  式(I)或(II)的化合物 其中R x ，R z ，R 9 ，R 10 ，R 14 ，R 14 ′，R 15 ，R 15 ′，A和B如权利要求中所定义，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于AR的疾病和病症中，需要AR拮抗作用时可用作药物。
• [EN] ANDROGEN RECEPTOR MODULATING CARBOXAMIDES<br/>[FR] CARBOXAMIDES MODULANT LES RÉCEPTEURS D'ANDROGÈNES
  申请人：ORION CORP

  公开号：WO2012143599A1

  公开（公告）日：2012-10-26

  Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  公式（I）中的化合物，其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B的定义如索赔中所述，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于雄激素受体的疾病和病症中特别有用，其中需要AR拮抗作用。
• Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
  申请人：FRANK Robert

  公开号：US20130029962A1

  公开（公告）日：2013-01-31

  Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

  含有杂环吡唑基的羧酰胺和脲化合物作为辣椒素受体配体，含有这些化合物的药物组合物，以及使用这些化合物治疗和/或抑制疼痛以及进一步疾病和/或疾病的方法。
• [EN] N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYL-AMIDES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019967A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of general formula (I), wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式（I）的化合物，其中R1、LP、HetAr1、（Het）Ar2和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011076678A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式I的化合物，其中R是氢或较低的烷基；R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基基团可选择地被较低的烷基，羟基，卤素或-( )p-芳基取代；n为0、1或2；o为0或1；p为0、1或2；R2为CF3，环烷基，可选择地被较低的烷氧基或卤素取代，或为茚-2-基，或为杂环烷基，可选择地被杂芳基取代，或为芳基或杂芳基，其中芳香环可选择地被来自较低的烷基，卤素，杂芳基，羟基， ，O ，O ，O -环烷基，O C( OH)( C1)(CH3)，S-较低的烷基，较低的烷氧基， -较低的烷氧基，较低的炔基或氰基，或-C(O)-苯基，-O-苯基，-O- -苯基，苯基或- -苯基选择的一个或两个取代基取代，其中苯环可选择地被卤素，-C(O)-较低的烷基，-C(O)OH或-C(O)O-较低的烷基取代，或芳香环可选择地被杂环烷基，O -氧杂环戊烷-3-基或O-四氢吡喃-4-基，可选择地被较低的烷基取代；X为键，-NR'-，- NH-，-CHR''-，-(CHR'')q-O-，-O-(CHR'')q-或-( )2-；Y为键或- -；R'为氢或较低的烷基，R''为氢，较低的烷基， ，较低的烷氧基，q为0、1、2或3；或其药学上适宜的酸盐。现已发现，该式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，躁郁症，注意力缺陷多动障碍（ADHD），与压力有关的疾病，如精神分裂症，帕金森病等神经疾病，阿尔茨海默病等神经退行性疾病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收异常，体温稳态异常，睡眠和昼夜节律异常，以及心血管疾病。

表征谱图